179 related articles for article (PubMed ID: 23136335)
1. The effect of lowering the prostate-specific antigen normal cutoff on referral rates to urology.
Shenker BS; Stern J
J Am Board Fam Med; 2012; 25(6):927-9. PubMed ID: 23136335
[TBL] [Abstract][Full Text] [Related]
2. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.
Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM
Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819
[TBL] [Abstract][Full Text] [Related]
3. Can delayed time to referral to a tertiary level urologist with an abnormal PSA level affect subsequent Gleason grade in the opportunistically screened population?
O'Kelly F; Thomas A; Murray D; Galvin D; Mulvin D; Quinlan DM
Prostate; 2013 Sep; 73(12):1263-9. PubMed ID: 23657938
[TBL] [Abstract][Full Text] [Related]
4. [Focus on the screening for prostate cancer by PSA].
Roumeguère T; Van Velthoven R
Rev Med Brux; 2013 Sep; 34(4):311-9. PubMed ID: 24195246
[TBL] [Abstract][Full Text] [Related]
5. Screening for prostate cancer: the current evidence and guidelines controversy.
Gomella LG; Liu XS; Trabulsi EJ; Kelly WK; Myers R; Showalter T; Dicker A; Wender R
Can J Urol; 2011 Oct; 18(5):5875-83. PubMed ID: 22018148
[TBL] [Abstract][Full Text] [Related]
6. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
7. PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer.
Otto SJ; Moss SM; Määttänen L; Roobol M; Zappa M; Nelen V; Kwiatkowski M; Villers A; Hugosson J; Sanchez AB; de Koning HJ
Eur J Cancer; 2010 Nov; 46(17):3053-60. PubMed ID: 21047586
[TBL] [Abstract][Full Text] [Related]
8. Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study.
Reissigl A; Pointner J; Horninger W; Ennemoser O; Strasser H; Klocker H; Bartsch G
Urology; 1995 Nov; 46(5):662-5. PubMed ID: 7495117
[TBL] [Abstract][Full Text] [Related]
9. Practitioner-level determinants of inappropriate prostate-specific antigen screening.
Kerfoot BP; Holmberg EF; Lawler EV; Krupat E; Conlin PR
Arch Intern Med; 2007 Jul; 167(13):1367-72. PubMed ID: 17620529
[TBL] [Abstract][Full Text] [Related]
10. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
[TBL] [Abstract][Full Text] [Related]
11. Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening.
Hutchinson R; Akhtar A; Haridas J; Bhat D; Roehrborn C; Lotan Y
Cancer; 2016 Dec; 122(24):3785-3793. PubMed ID: 27658175
[TBL] [Abstract][Full Text] [Related]
12. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Culp S; Porter M
BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
[TBL] [Abstract][Full Text] [Related]
13. The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme.
Roddam AW; Hamdy FC; Allen NE; Price CP;
BJU Int; 2007 Sep; 100(3):514-7. PubMed ID: 17542987
[TBL] [Abstract][Full Text] [Related]
14. Knowledge, attitude and practice regarding prostate specific antigen (PSA) and prostate biopsy.
Nazim SM; Raza SJ; Ather MH
J Coll Physicians Surg Pak; 2013 Jul; 23(7):529-30. PubMed ID: 23823969
[No Abstract] [Full Text] [Related]
15. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
[TBL] [Abstract][Full Text] [Related]
16. Use of electronic medical records to identify patients at risk for prostate cancer in an academic institution.
Erickstad L; Reed G; Bhat D; Roehrborn CG; Lotan Y
Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):85-9. PubMed ID: 21151199
[TBL] [Abstract][Full Text] [Related]
17. Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practice.
Gaylis FD; Choi JE; Hamilton Z; Dato P; Cohen E; Calabrese R; Prime H; Rosenbaum A; Kader AK
Urol Oncol; 2017 Nov; 35(11):663.e1-663.e7. PubMed ID: 28736250
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
[TBL] [Abstract][Full Text] [Related]
19. [PSA: the difficult position of general practitioners between patients and urologists].
Vincendeau S; Abi Moussa M; Manunta A; Patard JJ; Guillé F; Lobel B
Prog Urol; 2003 Apr; 13(2):252-5. PubMed ID: 12765060
[TBL] [Abstract][Full Text] [Related]
20. Abnormal PSA tests--delays in referral.
Stapleton AM; Johns RL; Kopsaftis T; Tamblyn DJ; Pinnock CB
Aust Fam Physician; 2008; 37(1-2):84-8. PubMed ID: 18239761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
